Evidence map›Paper›PMID 20194747›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2010

Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells.

Marco Mazzone, Laura M Selfors, John Albeck, Michael Overholtzer, Sanja Sale, Danielle L Carroll, Darshan Pandya, Yiling Lu, Gordon B Mills, Jon C Aster and 2 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 158 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Tissue engineering. Part C, Methods · 2021
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Marco MazzoneDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Laura M Selfors
John Albeck
Michael Overholtzer
Sanja Sale
Danielle L Carroll
Darshan Pandya
Yiling Lu
Gordon B Mills
Jon C Aster
Spyros Artavanis-Tsakonas
Joan S Brugge
Harvard University · USThe University of Texas MD Anderson Cancer Center · USBrigham and Women's Hospital · USMemorial Sloan Kettering Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0M
Tyrosine Kinase-Dependant and - Independent Pathways of EGFR in Breast Cancer ProP01CA099031 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUNG, MIEN-CHIE · 2003 to 2014
$11.6M
Protein CoreP01CA119070 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ASTER, JON C. · 2006 to 2016
$10.3M
Cell Interactions Controlling Neural DifferentiationR37NS026084 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI ARTAVANIS-TSAKONAS, SPYRIDON · 2004 to 2010
$4.2M
Cell Death Regulation in Lumen Formation and OncogenesisR01CA105134 · NCI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BRUGGE, JOAN SIEFERT · 2003 to 2012
$4.1M
Notch Signaling in Mammary Development and TumorigenesisR01CA098402 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI ARTAVANIS-TSAKONAS, SPYRIDON · 2003 to 2013
$3.6M
NCI NIH HHS P01 CA099031NCI NIH HHS P01 CA105134NCI NIH HHS P01 CA119070NCI NIH HHS P30 CA016672NCI NIH HHS P30CA16672NCI NIH HHS P50 CA098258NCI NIH HHS R01 CA098402NCI NIH HHS R01 CA105134NINDS NIH HHS R37 NS026084NINDS NIH HHS R37 NS26084
6 · The paper itself

Abstract

Aberrant activation of Notch receptors has been implicated in breast cancer; however, the mechanisms contributing to Notch-dependent transformation remain elusive because Notch displays dichotomous functional activities, promoting both proliferation and growth arrest. We investigated the cellular basis for the heterogeneous responses to Notch pathway activation in 3D cultures of MCF-10A mammary epithelial cells. Expression of a constitutively active Notch-1 intracellular domain (NICD) was found to induce two distinct types of 3D structures: large, hyperproliferative structures and small, growth-arrested structures with reduced cell-to-matrix adhesion. Interestingly, we found that these heterogeneous phenotypes reflect differences in Notch pathway activation levels; high Notch activity caused down-regulation of multiple matrix-adhesion genes and inhibition of proliferation, whereas low Notch activity maintained matrix adhesion and provoked a strong hyperproliferative response. Moreover, microarray analyses implicated NICD-induced p63 down-regulation in loss of matrix adhesion. In addition, a reverse-phase protein array-based analysis and subsequent loss-of-function studies identified STAT3 as a dominant downstream mediator of the NICD-induced outgrowth. These results indicate that the phenotypic responses to Notch are determined by the dose of pathway activation; and this dose affects the balance between growth-stimulative and growth-suppressive effects. This unique feature of Notch signaling provides insights into mechanisms that contribute to the dichotomous effects of Notch during development and tumorigenesis.

Indexed as

Signal TransductionCell AdhesionCell ProliferationCells, CulturedEpithelial CellsExtracellular MatrixFemaleHumansMammary Glands, HumanPhenotypeProtein Structure, TertiaryReceptor, Notch1STAT3 Transcription FactorTrans-ActivatorsTranscription FactorsTumor Suppressor ProteinsNOTCH1 protein, humanReceptor, Notch1STAT3 protein, humanSTAT3 Transcription FactorTP63 protein, humanTrans-ActivatorsTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID20194747
PMCPMC2841923
OpenAlexW1990490057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.